Tirzepatide
Dual receptor agonist. Outperforms semaglutide in head-to-head trials.
For research use only · Not for human consumption
Every source for Tirzepatide
Affiliate disclosure: purchases through links below may earn us a commission. Rankings are never sold — methodology · full disclosure
- ✓Third-party tested (Janoshik)
- ✓COAs provided — Per-batch core, quarterly bonus
- ✓Best $/mg in stock right now
- ✓4.8★ community rating
The research base
FDA approved. Phase 3 trials show superior metabolic effects vs single-receptor agonists.
How it works
Activates both GLP-1 and GIP receptors. Dual-pathway stimulation.
Common research protocols
Standard FDA titration for Mounjaro/Zepbound. Same molecule, same dosing ladder. Each step held 4 weeks minimum. If missing dose: take if >72 hours until next dose; otherwise skip. Dual GLP-1/GIP agonist — typically better GI tolerance than retatrutide at equivalent weight-loss efficacy.
As a solo compound
Highly effective alone. Dual-agonist mechanism is its key feature.
What to know
Common: GI adjustment. Well-tolerated overall.
Realistic expectations
Effects within 2-4 weeks